LncRNA GACAT3: A Promising Biomarker and Therapeutic Target in Human Cancers

被引:7
|
作者
Yuan, Xin [1 ]
Dong, Zihui [1 ,2 ]
Shen, Shen [1 ,2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affifiliated Hosp 1, Gene Hosp Henan Prov, Precis Med Ctr, Zhengzhou, Peoples R China
关键词
lncRNA; cancer; biomarker; GACAT3; molecular mechanisms; LONG NONCODING RNA; GASTRIC-CANCER; BREAST-CANCER; LUNG-CANCER; CELL-PROLIFERATION; PROMOTES; INVASION; EPIDEMIOLOGY; MIGRATION; LNCRNA-GACAT3;
D O I
10.3389/fcell.2022.785030
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Long non-coding RNAs (lncRNAs) are a class of functional RNA molecules that do not encode proteins and are composed of more than 200 nucleotides. LncRNAs play important roles in epigenetic and gene expression regulation. The oncogenic lncRNA GACAT3 was recently discovered to be dysregulated in many tumors. Aberrant expression of GACAT3 contributes to clinical characteristics and regulates multiple oncogenic processes. The association of GACAT3 with a variety of tumors makes it a promising biomarker for diagnosis, prognosis, and targeted therapy. In this review, we integrate the current understanding of the pathological features, biological functions, and molecular mechanisms of GACAT3 in cancer. Additionally, we provide insight into the utility of GACAT3 as an effective diagnostic and prognostic marker for specific tumors, which offers novel opportunities for targeted therapeutic intervention.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PKCι Is a Promising Prognosis Biomarker and Therapeutic Target for Pancreatic Cancer
    Abdelatty, Alaa
    Fang, Dan
    Wei, Guanqun
    Wu, Fubing
    Zhang, Chengfei
    Xu, Haojun
    Yao, Chengyun
    Wang, Yundong
    Xia, Hongping
    PATHOBIOLOGY, 2022, 89 (06) : 370 - 381
  • [32] IMP3 is a promising biomarker in urological cancers
    Nature Clinical Practice Urology, 2008, 5 (7): : 355 - 355
  • [33] Fascin actin-bundling protein 1 in human cancer: Promising biomarker or therapeutic target?
    Liu, Hongliang
    Zhang, Yu
    Li, Li
    Cao, Jimin
    Guo, Yujia
    Wu, Yongyan
    Gao, Wei
    MOLECULAR THERAPY-ONCOLYTICS, 2021, 20 : 240 - 264
  • [34] Characterization of URSTI as a biomarker and therapeutic target for respiratory tract cancers
    Takano, Atsushi
    Yoshihiro, Yoshitake
    Shinohara, Masanori
    Miyagi, Yohei
    Daigo, Yataro
    CANCER SCIENCE, 2018, 109 : 957 - 957
  • [35] LncRNA AK001796 as a therapeutic target in aggressive breast cancers
    Kumar, Maneesh
    DeVaux, Rebecca Sinnott
    Shen, Julia J.
    Davis, Steven P.
    Dinger, Marcel E.
    Mattick, John S.
    Perou, Charles M.
    Rosen, Jeffrey M.
    Mani, Sendurai A.
    Herschkowitz, Jason I.
    CANCER RESEARCH, 2016, 76
  • [36] Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers
    Yick Liang Lum
    Ester Khin
    Nikki P Lee
    John M Luk
    World Journal of Gastroenterology, 2012, 18 (30) : 3923 - 3930
  • [37] The Circadian Clock as a Potential Biomarker and Therapeutic Target in Gastrointestinal Cancers
    Barati, Sama
    Saffar, Homina
    Mehrabadi, Shima
    Avan, Amir
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (23) : 1804 - 1811
  • [38] Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers
    Cao, Dong-Xing
    Li, Zhi-Jie
    Jiang, Xiao-Ou
    Lum, Yick Liang
    Khin, Ester
    Lee, Nikki P.
    Wu, Guo-Hao
    Luk, John M.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (30) : 3923 - 3930
  • [39] LncRNA MALAT1: A Potential Fibrosis Biomarker and Therapeutic Target
    Li, Yijie
    Liu, Fenglin
    Cai, Yunzhou
    Yang, Yanqing
    Wang, Yuehong
    CRYSTALS, 2021, 11 (03) : 1 - 16
  • [40] GAS5 lncRNA: A biomarker and therapeutic target in breast cancer
    Thangavelu, Lakshmi
    Moglad, Ehssan
    Gupta, Gaurav
    Gaur, Ashish
    Menon, Soumya V.
    Sharma, Snehlata
    Kaur, Mandeep
    Chahar, Mamata
    Sivaprasad, G. V.
    Deorari, Mahamedha
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 260